Form 4: Sana Biotechnology Director Richard Mulligan Granted 80,000 Stock Options

Sana Biotechnology, Inc. has reported that Director Richard Mulligan was granted 80,000 stock options with an exercise price of $2.55, vesting by June 2026.

Summary

• Richard Mulligan, a Director of Sana Biotechnology, Inc. (SANA), was granted 80,000 stock options.
• The options have an exercise price of $2.55 per share.
• The options were granted on June 5, 2025, and are set to expire on June 4, 2035.
• The options will vest and become exercisable as to 100% of the underlying shares on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders, contingent on continuous service to Sana.
• Following this transaction, Mr. Mulligan beneficially owns 80,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and long-term incentives.

Positives

• The grant of stock options to Director Richard Mulligan aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive horizon for the director.

Future Outlook

The granted stock options are set to vest 100% on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, provided the reporting person continues to provide service to Sana Biotechnology.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and broader corporate sectors, serving as a standard form of equity compensation to attract, retain, and incentivize board members by aligning their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The grant of 80,000 stock options to a director is a typical form of equity compensation for board members in the biotechnology industry, comparable to practices seen in companies like Moderna or BioNTech, where equity incentives are used to align director interests with shareholder value creation.
• The vesting schedule and exercise price are standard for such grants, reflecting common compensation structures for non-employee directors.

Related Party Transactions

• The grant of stock options to Richard Mulligan, a Director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest 100% on the earlier of June 5, 2026, or immediately prior to Sana Biotechnology's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Sana Biotechnology, SANA, SEC Form 4, Stock Option Grant, Director Compensation, Richard Mulligan, Equity Compensation, Beneficial Ownership